ALK and non-small cell lung carcinoma: To answer the question of whether sequential treatment with alectinib after crizotinib is better than alectinib for ALK-positive NSCLC as an initial treatment, alectinib and crizotinib were previously compared as a first-line treatment for ALK-positive NSCLC.